Supernus Pharmaceuticals | SUPN - Gewinn Vor Steuern





Gewinn Vor Steuern Veränderung Datum
Abbott USD 2.39B 27M 2026-03
ANI Pharmaceuticals USD 31.48M 18.04M 2025-12
Aurora Cannabis CAD -1.58M 48.55M 2025-12
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Canopy Growth CAD -62.26M 60.84M 2025-12
Cara Therapeutics USD -4.91M 3.17M 2025-03
Corcept Therapeutics USD 9.91M 5.33M 2025-12
Eisai JPY -7.94B 29.94B 2026-03
Eli Lilly USD 8.27B 1.03B 2025-12
Novo Nordisk DKK 33.8B 3.23B 2025-06
Pacira USD 571K 8.95M 2025-12
Perrigo USD -1.33B 1.35B 2025-12
Pfizer USD 5.18B 6.82B 2026-03
Supernus Pharmaceuticals USD -5.95M 4.04M 2026-03
United Therapeutics USD 444M 6M 2025-12
Xeris Pharmaceuticals USD 11.08M 10.46M 2025-12